AXL and non-small cell lung carcinoma: Wang et al.’s (209) study also found that although NSCLC cells with low expression of AXL were more sensitive to osimertinib, there still existed a small group of cells activated by IGF-1R signaling that were resistant to osimertinib treatment, while the use of IGF-1R inhibitors could prevent the generation of DTP cells.